ADAMTS13 and hyperinsulinemic hypoglycemia, familial, 4: A phase I study that evaluated the safety, tolerability, and pharmacokinetics of rADAMTS13 (BAX 930) in patients with severe congenital ADAMTS13 deficiency found that it was well tolerated, with no serious adverse events or formation of anti-ADAMTS13 antibodies [71].